Literature DB >> 12477490

Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon.

Jean Pierre Raynaud1, Henri Cousse, Pierre Marie Martin.   

Abstract

In different cell systems, the lipido-sterolic extract of Serenoa repens (LSESr, Permixon inhibits both type 1 and type 2 5alpha-reductase activity (5alphaR1 and 5alphaR2). LSESr is mainly constituted of fatty acids (90+/-5%) essentially as free fatty acids (80%). Among these free fatty acids, the main components are oleic and lauric acids which represent 65% and linoleic and myristic acids 15%. To evaluate the inhibitory effect of the different components of LSESr on 5alphaR1 or 5alphaR2 activity, the corresponding type 1 and type 2 human genes have been cloned and expressed in the baculovirus-directed insect cell expression system Sf9. The cells were incubated at pH 5.5 (5alphaR2) and pH 7.4 (5alphaR1) with 1 or 3nM testosterone in presence or absence of various concentrations of LSESr or of its different components. Dihydrotestosterone formation was measured with an automatic system combining HPLC and an on-line radiodetector. The inhibition of 5alphaR1 and 5alphaR2 activity was only observed with free fatty acids: esterified fatty acids, alcohols as well as sterols assayed were inactive. A specificity of the fatty acids in 5alphaR1 or 5alphaR2 inhibition has been found. Long unsaturated chains (oleic and linolenic) were active (IC(50)=4+/-2 and 13+/-3 microg/ml, respectively) on 5alphaR1 but to a much lesser extent (IC(50)>100 and 35+/-21 microg/ml, respectively) on 5alphaR2. Palmitic and stearic acids were inactive on the two isoforms. Lauric acid was active on 5alphaR1 (IC(50)=17+/-3 microg/ml) and 5alphaR2 (IC(50)=19+/-9 microg/ml). The inhibitory activity of myristic acid was evaluated on 5alphaR2 only and found active on this isoform (IC(50)=4+/-2 microg/ml). The dual inhibitory activity of LSESr on 5alpha-reductase type 1 and type 2 can be attributed to its high content in free fatty acids.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477490     DOI: 10.1016/s0960-0760(02)00187-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  20 in total

Review 1.  Saw palmetto and lower urinary tract symptoms: what is the latest evidence?

Authors:  Andrew L Avins; Stephen Bent
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

2.  Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of ((3)H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Más; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

3.  In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Má; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

Review 4.  Use of saw palmetto (Serenoa repens) extract for benign prostatic hyperplasia.

Authors:  Youngjoo Kwon
Journal:  Food Sci Biotechnol       Date:  2019-04-17       Impact factor: 2.391

Review 5.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

6.  Influence of commercial dietary oils on lipid composition and testosterone production in interstitial cells isolated from rat testis.

Authors:  Graciela E Hurtado de Catalfo; María J T de Alaniz; Carlos Alberto Marra
Journal:  Lipids       Date:  2009-01-08       Impact factor: 1.880

7.  Effects of D-004, a lipid extract of the fruit of the Cuban royal palm (Roystonea regia) or the lipidosterolic extract of saw palmetto (Serenoa repens) on the sexual activity in male rats: A controlled, experimental study.

Authors:  Lilia C Fernández; Rosa Mas; Julio Fernández; Sarahí Mendoza; Rafael Gámez; Balia Pardo
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

8.  Benign prostatic hyperplasia: An overview of existing treatment.

Authors:  Neelima Dhingra; Deepak Bhagwat
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

9.  Fatty acid and phytosterol content of commercial saw palmetto supplements.

Authors:  Kavitha Penugonda; Brian L Lindshield
Journal:  Nutrients       Date:  2013-09-13       Impact factor: 5.717

10.  Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.

Authors:  Nanor Sirab; Grégoire Robert; Virginie Fasolo; Aurélien Descazeaud; Francis Vacherot; Alexandre de la Taille; Stéphane Terry
Journal:  Int J Mol Sci       Date:  2013-07-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.